Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Finlayson

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Journal of Medicinal Chemistry|September 19, 2012
Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitorsJames J Crawford, Peter W Kenny, Jonathan Bowyer, et al.
Journal of Medicinal Chemistry|June 30, 2012
(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritisAlexander G Dossetter, Howard Beeley, Jonathan Bowyer, et al.
Expert Review of Clinical Pharmacology|December 10, 2014
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?Brian Godman, Rickard E Malmström, Eduardo Diogene, et al.
Frontiers in Pharmacology|May 30, 2013
Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugsRickard E Malmström, Brian B Godman, Eduard Diogene, et al.
BMC Medicine|August 15, 2013
Personalizing health care: feasibility and future implicationsBrian Godman, Alexander E Finlayson, Parneet K Cheema, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Journal of Medicinal Chemistry|September 19, 2012
Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitorsJames J Crawford, Peter W Kenny, Jonathan Bowyer, et al.
Journal of Medicinal Chemistry|June 30, 2012
(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritisAlexander G Dossetter, Howard Beeley, Jonathan Bowyer, et al.
Expert Review of Clinical Pharmacology|December 10, 2014
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?Brian Godman, Rickard E Malmström, Eduardo Diogene, et al.
Frontiers in Pharmacology|May 30, 2013
Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugsRickard E Malmström, Brian B Godman, Eduard Diogene, et al.
BMC Medicine|August 15, 2013
Personalizing health care: feasibility and future implicationsBrian Godman, Alexander E Finlayson, Parneet K Cheema, et al.
Pageof 7